Have a feature idea you'd love to see implemented?
Let us know!
SGMO Sangamo Therapeutics Inc
Price (delayed)
$1.49
Market cap
$310.25M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.38
Enterprise value
$311.56M
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, cell therapy, and genome engineering.
Highlights
SGMO's debt is down by 20% YoY and by 6% QoQ
Sangamo Therapeutics's net income has decreased by 26% YoY but it has increased by 24% QoQ
The EPS is up by 26% since the previous quarter but it has declined by 16% year-on-year
The revenue has dropped by 94% year-on-year and by 35% since the previous quarter
The gross profit has shrunk by 94% YoY and by 35% QoQ
Key stats
What are the main financial stats of SGMO
Market
Valuations
Earnings
Shares outstanding
208.22M
Market cap
$310.25M
Enterprise value
$311.56M
Price to earnings (P/E)
N/A
Price to book (P/B)
13.05
Price to sales (P/S)
24.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.38
Revenue
$12.28M
EBIT
-$248.51M
EBITDA
-$232.98M
Free cash flow
-$178.79M
Per share
Balance sheet
Liquidity
EPS
-$1.38
Free cash flow per share
-$0.88
Book value per share
$0.11
Revenue per share
$0.06
TBVPS
$0.46
Total assets
$93.01M
Total liabilities
$69.32M
Debt
$29.1M
Equity
$23.69M
Working capital
$1.07M
Debt to equity
1.23
Current ratio
1.03
Quick ratio
0.73
Net debt/EBITDA
-0.01
Margins
Efficiency
Dividend
EBITDA margin
-1,897.7%
Gross margin
100%
Net margin
-2,033.7%
Operating margin
-2,094%
Return on assets
-164.5%
Return on equity
-334.9%
Return on invested capital
-267.1%
Return on capital employed
-460.1%
Return on sales
-2,024.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SGMO stock price
How has the Sangamo Therapeutics stock price performed over time
Intraday
-3.25%
1 week
59.24%
1 month
60.87%
1 year
206.84%
YTD
174.25%
QTD
72.04%
Financial performance
How have Sangamo Therapeutics's revenue and profit performed over time
Revenue
$12.28M
Gross profit
$12.28M
Operating income
-$257.08M
Net income
-$249.68M
Gross margin
100%
Net margin
-2,033.7%
The revenue has dropped by 94% year-on-year and by 35% since the previous quarter
The gross profit has shrunk by 94% YoY and by 35% QoQ
Sangamo Therapeutics's net income has decreased by 26% YoY but it has increased by 24% QoQ
The operating income has grown by 25% from the previous quarter but it has contracted by 19% YoY
Growth
What is Sangamo Therapeutics's growth rate over time
Valuation
What is Sangamo Therapeutics stock price valuation
P/E
N/A
P/B
13.05
P/S
24.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.38
The EPS is up by 26% since the previous quarter but it has declined by 16% year-on-year
The equity has shrunk by 90% YoY and by 58% QoQ
The revenue has dropped by 94% year-on-year and by 35% since the previous quarter
Efficiency
How efficient is Sangamo Therapeutics business performance
The ROE has contracted by 30% from the previous quarter
The return on sales has declined by 14% since the previous quarter
Sangamo Therapeutics's return on invested capital has decreased by 11% QoQ
The company's return on assets fell by 5% QoQ
Dividends
What is SGMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SGMO.
Financial health
How did Sangamo Therapeutics financials performed over time
SGMO's total assets is 34% greater than its total liabilities
The quick ratio has dropped by 73% year-on-year and by 47% since the previous quarter
SGMO's total assets has dropped by 71% year-on-year and by 28% since the previous quarter
SGMO's debt is 23% higher than its equity
Sangamo Therapeutics's debt to equity has surged by 128% QoQ
The equity has shrunk by 90% YoY and by 58% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.